We and others have previously documented increased resting and exercise-induced skeletal muscle blood flow in young subjects with Type I (insulin-dependent) diabetes mellitus compared with healthy controls. Both NO and prostanoids are important regulators of vascular tone and may therefore contribute to this hyperaemia. The aim of the present study was to determine the contribution of NO and vasodilator prostanoids to this skeletal muscle hyperaemia in diabetes.
INTRODUCTION
The haemodynamic hypothesis of diabetic microangiopathy details the pathophysiological events in the development of microvascular disease [1, 2] . A cornerstone of this is the early development of microcirculatory hyperaemia, which has been demonstrated in the retinal in response to exercise and to reactive hyperaemia is dependent not only on systemic influences, such as the autonomic nervous system, but also on local vasoactive metabolites [8] and endothelium-dependent paracrine factors, such as nitric oxide (NO) [9] [10] [11] , and the vasoactive prostanoids, principally prostacyclin (prostaglandin I # ) [12] [13] [14] . We and others have demonstrated an impaired NO-mediated vasodilator response to various stimuli in subjects with Type I diabetes [7, [15] [16] [17] [18] . These findings raise the possibility that, in conditions associated with endothelial vasodilator dysfunction, such as Type I diabetes, abnormal NO-mediated regulation of blood flow might be expected.
In the setting of impaired NO-mediated vasodilation, increased levels of prostacyclin could potentially be responsible for the hyperaemia that is observed in the skeletal muscle circulation of subjects with Type I diabetes. Conflicting reports suggest that levels of this prostanoid are increased [19] [20] [21] , normal or reduced [22] [23] [24] in diabetes. Acetylsalicylic acid (ASA ; aspirin), which rapidly inhibits prostaglandin formation by inactivating cyclo-oxygenase, can be used to assess the contribution of prostacyclin to this skeletal muscle hyperaemia [13, 25] . In turn, the contribution of NO can be assessed following the infusion of N G -monomethyl-Larginine (L-NMMA), an L-arginine analogue which is used to inhibit the synthesis of NO [26] .
We hypothesized that augmented production of prostacyclin, but not of NO, might be responsible for skeletal muscle hyperaemia in subjects with Type I diabetes mellitus.
These data were presented in part at the 70th Scientific Sessions of the American Heart Association in November 1997, and have been published in Abstract form [26a] .
METHODS

Subjects
Subjects with Type I diabetes (DM subjects) and healthy control subjects were recruited by advertisement to participate in this study. Subjects who had participated in the first study were subsequently recruited for the second part of the investigation (13 DM subjects and 20 controls received ASA, while 9 DM subjects and 11 controls received L-NMMA). The study was approved by the Human Research Ethics Committee of Monash Medical Centre, and all subjects were fully informed and provided written informed consent. The investigation conforms with the principles outlined in the Declaration of Helsinki.
Participants were clinically well, and were screened for cardiovascular risk factors and disease with a medical history, physical examination, full fasting lipid profile, fasting glucose level, urea, creatinine and liver function tests. Subjects were excluded if there were any signs of Table 1 . There were no differences in age, gender distribution, body mass index or conventional cardiovascular risk factors between the groups. In addition, there were no differences in fasting total cholesterol, triacylglycerols, low-density lipoprotein (LDL)-cholesterol or highdensity lipoprotein (HDL)-cholesterol between the two groups.
DM subjects were all controlled with insulin. The average daily total insulin dose was 71p18 units (range 42-174 units). The duration of diabetes was 113p50 months, with at least fair metabolic control, as represented by levels of glycosylated haemoglobin (Hb A "C ) (8.6p0.3 %). Timed overnight urine collections were performed in DM subjects to assess albumin excretion rates, which were within normal limits (14.1p 3.4 µg\min). None of the DM subjects had clinical evidence of retinopathy or neuropathy.
General procedures
All studies were performed in the morning in a dedicated, quiet, climate-controlled laboratory (22-23 mC) with dimmed lighting. Subjects attended the laboratory fasted, having refrained from ASA (aspirin) and non-steroidal anti-inflammatory drugs for at least 5 days before the study, and from caffeine-containing beverages for 12 h. Each subject was given a standardized light breakfast, before which DM subjects received their usual insulin dose. Blood glucose levels were documented in DM subjects at the time of measurement of basal flow and exercise-related blood flow. It was the intention of this Prostanoids, nitric oxide and hyperaemia in Type I diabetes Immediately on cessation of exercise, peak functional hyperaemic blood flow can be measured. The area under the flow-time curve represents the volume repaid to the forearm at 5 min (AUC 5). By subtracting basal volume from AUC 5, the absolute volume repaid to the forearm can be calculated (∆AUC 5).
study to investigate diabetic patients in their usual state, but, in order to avoid the potentially confounding haemodynamic effects of marked hyperglycaemia or hypoglycaemia, a prospective decision was made to exclude any individual whose blood glucose deviated from the range 5-20 mmol\l during the study. No active treatment was given for control of blood glucose during the study, and no subjects required exclusion.
Studies were performed with the subject in the supine position. A 20-gauge, 5 cm polyethylene catheter (Cook, Brisbane, Australia) was introduced into the brachial artery of the non-dominant forearm under local anaesthesia utilizing aseptic conditions. The arterial line was used for on-line measurement of blood pressure and for direct intra-arterial drug infusions. The catheter was connected via a minimum-dead-space saline-filled line to a pressure transducer (Biosensors International, Singapore). Physiological saline was infused at a rate of 0.4 ml\min through the catheter into the brachial artery to maintain patency. Forearm blood flow (FBF ; in units of ml:min −" :100 ml −" forearm tissue) was measured at rest and in response to both endothelium-dependent and -independent vasodilators infused directly into the brachial artery, as described previously [13] . In brief, measurement of blood flow was achieved by the well validated technique of venous occlusion plethysmography [27] using a calibrated mercury-in-silastic strain gauge (D. E. Hokanson, Bellevue, WA, U.S.A.). During the recording of FBF, the hands were excluded from the circulation by inflation of a wrist cuff to suprasystolic pressure. Venous occlusion pressure was 40 mmHg. Measurement of resting FBF was carried out at least 30 min after insertion of the brachial artery line, and at least 2 h after insulin injection in DM subjects. Furthermore, measurement of resting FBF was repeated until a stable recording was obtained.
FBF responses were measured continuously for 2 min following infusion of each dose of drug. An average FBF was calculated from at least five venous occlusion cycles. Baseline flow was re-measured at least 10 min after the completion of each drug sequence, and this was repeated until a stable recording similar to the original basal FBF value was again achieved. This was achieved on average in 13 min. Mean arterial pressure (MAP) was measured online. Forearm vascular resistance (FVR) was calculated by dividing MAP by FBF, and was expressed in arbitrary units.
Drug infusion protocol
The volume of the non-dominant forearm was measured in each subject by water displacement. Acetylcholine (ACh) chloride (Miochol ; Iolab Pharmaceuticals, Sydney, Australia), an endothelium-dependent NOmediated vasodilator, was infused into the brachial artery for 3 min at doses of 2.7, 9 and 27 µg\min. Sodium nitroprusside (SNP) (Faulding, Melbourne, Australia), an endothelium-independent vascular smooth muscle vasodilator, was infused into the brachial artery for 3 min at a dose of 9 µg\min. ASA (ASPISOL ; Bayer) was infused into the brachial artery at a dose of 10 mg\min, as previously described [13, 25] , to achieve a local plasma concentration (assuming an FBF of 2.5 ml:min −" :100 ml −" forearm) of 500 µg\ml. L-NMMA (Clinalfa AG, Laufelfingen, Switzerland) was infused at a dose of 2 mg\min. After dilution in normal saline, all drugs were infused at a rate of 0.4 ml\min using a syringe pump (Terumo Corp., Tokyo, Japan). 
Functional hyperaemia
Functional hyperaemic blood flow was measured in response to 2 min of isotonic wrist flexion and extension exercise against no load, paced by a metronome at 45 cycles\min. This stimulus has been shown to be reproducible in our laboratory [25] . Peak functional hyperaemic FBF (PFBF) was measured immediately on cessation of exercise, and flow measurement was repeated for 5 min thereafter, similar to the procedure described previously for reactive hyperaemia [11] . Flow was measured every 7 s during the first 2 min post-exercise, and 5 times per min thereafter. This enabled the construction of a post-exercise flow decay curve for each individual patient, as shown in Figure 1 . The absolute increase in hyperaemic flow following exercise (∆PFBF) was calculated by subtracting basal FBF immediately prior to exercise from PFBF. Furthermore, the area under the flow-time decay curve (representing the hyperaemic volume repaid to the forearm) was calculated at the arbitrary time interval of 5 min (AUC 5). The absolute hyperaemic volume repaid to the forearm 5 min after exercise (∆AUC 5) was also calculated by subtracting the basal volume (basal flowitime) from the total hyperaemic volume at 5 min.
In order to ensure acceptable reproducibility of this technique during the study, we examined forearm exercise on three separate occasions within one morning in a group of nine healthy subjects. The within-day reproducibility of the technique was found to be acceptable, with a coefficient of variation of 4.2 %, 6.3 % and 7.2 % for resting FBF, PFBF and ∆AUC 5 respectively.
Study protocol
Stable resting FBF was measured during the infusion of physiological saline solution, as shown in Figure 2 .
Subsequently, the response to 2 min of isotonic exercise was measured, followed by a dose-response curve to ACh and the response to SNP. ASA or L-NMMA infusion was subsequently carried out for 10 min to record the effect of inhibition of cyclo-oxygenase or NO synthase respectively on basal flow. This infusion was then continued while investigating the effects of ASA or L-NMMA on functional hyperaemia and the responses to ACh and SNP. After each stimulus, a stable resting FBF value, similar to that achieved at the beginning of the study, was obtained before proceeding.
In each individual subject, the two studies (involving infusion of ASA in one and L-NMMA in the other) were completed within 1 week. The average duration of each study was 222 min (range 198-242 min).
Statistical analysis
Clinical characteristics are expressed as meanspS.D. Data are expressed as meanspS. E. M. Student's t-test was utilized in the comparison of paired data (baseline characteristics, basal flow, exercise parameters). Assessment of the relative effect of ASA or L-NMMA in the two study groups was performed using two-way repeatedmeasures ANOVA. Statistical significance was accepted where P 0.05.
RESULTS
Effect of L-NMMA infusion on resting FBF
Intra-arterial infusion of L-NMMA produced a 48 % reduction in resting FBF in the control group (2.1p0.2 to 1.1p0.1 ml:min −" :100 ml −" forearm ; P 0.0005), with reciprocal changes in FVR (42.7p4.1 to 70.4p7.2 units ; P 0.005). In DM subjects, infusion of L-NMMA resulted in a non-significant 12 % reduction in resting FBF (3.4p0.5 to 3.0p0.5 ml:min −" :100 ml −" forearm). The magnitude of the decrease in FBF was greater in the control subjects (ANOVA ; P 0.05). Following the infusion of L-NMMA there was still a significant difference in resting FBF between the groups (DM subjects, 3.0p0.5 ml:min −" :100 ml −" forearm ; controls, 1.1p 0.1 ml:min −" :100 ml −" forearm ; P 0.005) (Figure 3a) . There was no significant change in MAP following infusion of L-NMMA.
Effect of ASA infusion on resting FBF
Intra-arterial infusion of ASA produced a 33 % decrease in resting FBF in DM subjects (from 3.9p0.4 to 2.6p0.3 ml:min −" :100 ml −" forearm ; P 0.005) ( Figure  3b ). There was a decrease of 21 % in FBF in the control group (2.8p0.2 to 2.2p0.2 ml:min −" :100 ml −" forearm ; P 0.05). The magnitude of the reduction was, however, greater in DM than in control subjects (P 0.005). The (b) ASA (black bars) reduced FBF in both DM (P 0.005) and control (P 0.05) subjects. However, the magnitude of the decrease in FBF following ASA was greater in DM subjects than in controls (ANOVA, P 0.005). ASA eliminated the difference in FBF between the two groups (DM subjects, 2.6p0.3 ml:min − 1 :100 ml − 1 forearm ; controls, 2.2p0.2 ml:min − 1 :100 ml − 1 forearm ; P l 0.14).
P<0.05 (a) Following the intra-arterial infusion of L-NMMA (black bars), ∆PFBF was reduced in the control group (P 0.05), but not in the diabetic group. (b) ASA (black bars) reduced ∆PFBF in both DM (P 0.05) and control (P 0.05) subjects. However, the magnitude of the reduction in ∆PFBF following ASA was greater in DM subjects than in controls (ANOVA, P 0.005). ASA eliminated the difference in ∆PFBF between the two groups.
infusion of ASA eliminated the difference in FBF between the DM and control groups (2.6p0.3 and 2.2p0.2 ml:min −" :100 ml −" forearm respectively ; P l 0.14). There were reciprocal changes in FVR.
The infusion of ASA did not produce any changes in MAP in either the DM subjects (pre-ASA, 87p3 mmHg ; post-ASA, 85p2 mmHg) or the controls (pre-ASA, 84p2 mmHg ; post-ASA, 85p3 mmHg), and there was no significant difference in MAP between the two groups either before or after ASA infusion.
Effect of L-NMMA infusion on PFBF following exercise
L-NMMA reduced PFBF by 29 % in control subjects (from 11.5p1.4 to 8.1p0.9 ml:min −" :100 ml −" forearm ; (a) Following the intra-arterial infusion of L-NMMA (black bars), ∆AUC 5 was reduced in the control group (P 0.0005), but not significantly so in the diabetic group. (b) ASA (black bars) reduced ∆AUC 5 in both DM (P 0.05) and control (P 0.05) subjects. The magnitude of the reduction in ∆AUC 5 following ASA was greater in DM subjects than in controls (ANOVA, P 0.005). ASA eliminated the difference in ∆AUC 5 between the two groups.
P 0.05). There was no reduction in PFBF in DM subjects. Similarly, L-NMMA reduced ∆PFBF in the control group (9.3p0.3 to 7.8p0.9 ml:min −" :100 ml −" forearm ; P 0.05), whereas ∆PFBF remained virtually unchanged in DM subjects (11.4p2.8 to 12.4p2.8 ml:min −" :100 ml −" forearm). The magnitude of the response to L-NMMA was greater in controls than in DM subjects (ANOVA, P 0.05) (Figure 4a ).
Effect of ASA infusion on PFBF following exercise
PFBF was reduced following the infusion of ASA in both DM subjects (17.6p1.9 to 13.6p1.6 ml:min −" :100 ml −" forearm ; P 0.05) and control subjects (13.7p0.6 to 11.8p0.9 ml:min −" :100 ml −" forearm ; P 0.05). Following the infusion of ASA there was no significant difference in PFBF between the two groups (DM, 13.6p1.6 ml:min −" :100 ml −" forearm ; control, 11.8p0.9 ml:min −" :100 ml −" forearm). Similarly, ∆PFBF was reduced in DM subjects and controls following the infusion of ASA. ASA again eliminated the difference in ∆PFBF between the two groups (DM, 10.7p1.4 ml:min −" :100 ml −" forearm ; control, 9.0p 0.8 ml:min −" :100 ml −" forearm) (Figure 4b ).
Effect of L-NMMA infusion on volume repaid following exercise
There was a 39 % reduction in volume repaid to the forearm (AUC 5) in response to L-NMMA in the control group (21.4p2.4 to 13.0p1.7 ml\100 ml forearm ; P 0.0005), whereas there was no significant change in AUC 5 in DM subjects (31.1p5.1 to 27.6p4.1 ml\100 ml forearm). The magnitude of the reduction in AUC 5 in response to L-NMMA was greater in controls than in DM subjects (ANOVA, P 0.05).
The absolute volume repaid at 5 min (∆AUC 5) was reduced by 35 % in response to L-NMMA in the control group (from 12.1p0.8 to 7.9p1.2 ml\100 ml forearm ; P 0.0005), but was not significantly reduced in DM subjects (17.7p2.1 to 15.2p2.0 ml\100 ml forearm). The relative effect of L-NMMA on ∆AUC 5 was greater in controls than in DM subjects (ANOVA, P 0.05) (Figure 5a ).
Effect of ASA infusion on volume repaid following exercise
ASA infusion reduced AUC 5 to a greater extent in DM subjects than in controls (ANOVA, P 0.05). In DM subjects this reduction was 33 % (from 33.6p4.0 to 22.5p2.3 ml:min −" :100 ml −" forearm ; P 0.0005), while the reduction in controls was 20 % (from 23.9p1.2 to 19.6p1.4 ml:min −" :100 ml −" forearm). The infusion of ASA eliminated the difference between the DM and control groups in AUC 5 values.
Similarly, ASA eliminated the difference in ∆AUC 5 values between the two groups, as a consequence of a greater reduction in blood flow in the DM compared with the control subjects (Figure 5b) . Prostanoids, nitric oxide and hyperaemia in Type I diabetes 
Effect of L-NMMA infusion on response to ACh
In view of the differences in basal FBF, we calculated the absolute changes in FBF and FVR in response to ACh. The vasodilator response to graded intra-arterial infusion of ACh was impaired in DM subjects compared with controls (ANOVA, P 0.05), with reciprocal changes in FVR (ANOVA, P 0.05) (Figure 6a ). At the highest dose of ACh (27 µg\min), the absolute change in FBF was reduced in DM subjects (8.0p1.2 ml:min −" : 100 ml −" forearm) compared with controls (13.0p 1.6 ml:min −" :100 ml −" forearm ; P 0.05). The slope of the dose-response curve was also reduced in DM subjects (0.25p0.04) compared with controls (0.42p0.06 ; P 0.05).
Following the infusion of L-NMMA there was significant blunting of the vasodilator response to ACh in the control group (ANOVA, P 0.05), but no significant change in DM subjects (Figures 6b and 6c) . In the control group absolute FBF at the highest dose of ACh was reduced from 13.0p1.6 to 5.1p1.8 ml:min −" :100 ml −" forearm following the infusion of L-NMMA (P 0.005). In DM subjects the decrease in absolute FBF produced by L-NMMA at the highest dose of ACh was from 8.0p1.2 to 6.9p0.8 ml:min −" :100 ml −" forearm (not significant). After the infusion of L-NMMA there was no significant difference in the vasodilator response to the graded intra-arterial infusion of ACh in DM compared with control subjects (ANOVA) (Figure 6d ).
Effect of L-NMMA infusion on response to SNP
The response to SNP was not significantly different in DM subjects compared with controls (4.7p0.5 and 3.9p0.5 ml:min −" :100 ml −" forearm respectively). The infusion of L-NMMA did not produce any change in the response to the endothelium-independent agonist (DM subjects, 4.5p0.6 ml:min −" :100 ml −" forearm ; controls, 4.1p0.5 ml:min −" :100 ml −" forearm ; P 0.05).
DISCUSSION
The results of the present study confirm our previous findings that resting FBF and FHBF are increased in young subjects with Type I diabetes mellitus [7] . L-NMMA, at a dose sufficient to reduce resting FBF in control subjects by 48 % and also to reduce FHBF, had no significant effect on the forearm hyperaemia observed in subjects with Type I diabetes. However, ASA reduced blood flow to a greater extent in DM subjects than in controls, and indeed eliminated the relative resting and exercise-induced skeletal muscle hyperaemia observed in the group with diabetes. These results suggest that vasodilator prostanoids may account for skeletal muscle hyperaemia in patients with Type I diabetes.
Endothelium-dependent paracrine factors are important in the control of vascular tone. NO is an important determinant of both resting [9, 10, 13, 28] and exerciseinduced [9, 10, 25, 28] blood flow in healthy subjects. However, in Type I diabetes, numerous [7, [15] [16] [17] [18] 29, 30] , but not all [31] [32] [33] , studies have demonstrated impaired shear-stress-mediated or agonist-induced NO-dependent vasodilation in both the conduit and resistance circulations. It is therefore not surprising that in the present study, as in others [31, 34] , a reduced contribution of NO to resting blood flow was observed in subjects with Type I diabetes.
Previous studies have not, however, assessed the contribution of NO to exercise-induced vasodilation in diabetes. We have shown previously that NO contributes approximately 30 % to metabolic vasodilation during exercise in healthy individuals [35] . In the present study we observed a reduced response to L-NMMA in the diabetic group with respect to all parameters of isotonic exercise. These findings suggest that NO-dependent vasodilation during submaximal exercise is impaired in the forearm circulation of patients with Type I diabetes.
Vasodilator prostanoids also make an important contribution to both resting and exercise-induced hyperaemia in health [12] [13] [14] 25] . Data from our laboratory have demonstrated that infusion of the cyclo-oxygenase inhibitor ASA will produce a dose-dependent reduction in FBF [13, 25] which correlates with diminished production of 6-oxo-prostaglandin F " α , the stable metabolite of prostacyclin. In addition, this effect of ASA does not appear to be related to non-specific actions of ASA, such as alterations in plasma pH or modulation of local noradrenaline release or uptake [13] . In healthy subjects prostacyclin accounts for approx. 20 % of resting and exercise-related blood flow (AUC 5), whereas the contribution is approx. 33 % in subjects with Type I diabetes. To account for this disparity it is possible that, in conditions of impaired bioavailability of NO (such as Type I diabetes), up-regulation of other endotheliumdependent factors, such as vasodilator prostanoids, may result. As a consequence these substances would play a more prominent role in the control of vascular tone. In keeping with this hypothesis, altered prostanoid production by renal glomeruli (involving increases in vasodilatory prostanoid and decreases in vasoconstrictor prostanoid levels) has been suggested to mediate the hyperfiltration that occurs during the early stages of diabetic nephropathy [36, 37] .
Our findings are consistent with two previous studies demonstrating elevated levels of prostacyclin in diabetic patients [20, 21] . However, interpretation of studies examining prostacyclin production in diabetes are complicated not only by age [22, 23, 38] , variation in metabolic parameters [19, 39] and duration of disease [40] , but also by the presence of micro-and macro-vascular complications [39, 41] .
Augmented production of vasoactive prostanoids in diabetes could be related to alterations in aldose reductase activity [42] , changes in shear stress [43] or changes in circulating glucose and insulin levels [44] . Insulin is a potent vasodilator that is thought to act, at least in part, through an endothelium-dependent NO-mediated mechanism [45, 46] , but also through other pathways such as prostacyclin [47] . Peripheral insulin levels are known to be elevated in Type I diabetes [48] , and these levels are directly related to both resting and exercise-induced hyperaemia [7] . It is thus possible that elevated insulin levels produce relative hyperaemia in subjects with Type I diabetes via a prostacyclin-mediated mechanism, which is susceptible to the effects of ASA.
The results of the present study may have important implications with respect to other regional circulations, particularly those of the retina and kidney, where hyperaemia is thought to lead to microvascular complications [1, 2] . If it can be demonstrated that vasodilator prostanoids are also responsible for this phenomenon, ASA may be a therapeutic agent with which to intervene early in the pathogenesis of diabetic retinopathy and nephropathy. However, it should be emphasized that the doses of ASA used in the present study are within the anti-inflammatory range, and the relevance of standard oral doses of ASA (75-325 mg) to the findings presented here are not clear. Notably, 325 mg of ASA appeared to have no effect on FBF responses in Type II (non-insulindependent) diabetes [49] , suggesting that high-dose ASA is required to adequately block synthesis of vasodilator prostanoids.
Although a reduced response to L-NMMA is widely interpreted as evidence of reduced release of NO, it is possible, particularly in the presence of augmented blood flow, that there is in fact increased NO synthesis. Consequently this would require more L-NMMA to overcome the associated dilation. However, the impaired vasodilator response to ACh, together with the effect of L-NMMA on skeletal muscle haemodynamics in the diabetic patients in the present study, suggests that reduced NO bioavailability is the more likely interpretation. Impaired endothelial uptake or metabolism of L-NMMA is a further possibility that may account for an impaired response to this NO synthase inhibitor. Until we are able to directly and accurately measure basal and stimulated NO production, conclusive proof of reduced bioavailability of NO will be lacking.
Measurement of alterations in the levels of 6-oxoprostaglandin F " α (the stable metabolite of prostacyclin) in response to ASA would have provided corroborating evidence regarding our proposed mechanism underlying forearm hyperaemia in Type I diabetes. This was not performed in the present study although, as discussed above, we have shown previously in healthy controls a direct correlation between FBF and 6-keto-prostaglandin F " α levels following ASA infusion [13] . Moreover, nonspecific effects of ASA do not account for the reduction in blood flow seen following ASA infusion [13] . Furthermore, the fact that ASA reduced, rather than increased, blood flow provides evidence that vasoconstrictor prostanoids do not appear to be important in the control of blood flow in diabetic subjects.
In conclusion, we have evidence from the present study of a reduced contribution of NO to resting and exercise-induced hyperaemia in subjects with Type I diabetes. The fact that the infusion of ASA eliminates the relative hyperaemia at rest and associated with exercise provides evidence that this phenomenon may be related to the increased release of vasodilator prostanoids. This finding may have important implications for the treatment of augmented microvascular blood flow in subjects with Type I diabetes.
